Risk factors for heart disease in transfusion-dependent thalassemia: serum ferritin revisited

被引:12
|
作者
Derchi, Giorgio [1 ]
Dessi, Carlo [2 ]
Bina, Patrizio [2 ]
Cappellini, Maria Domenica [3 ]
Piga, Antonio [4 ]
Perrotta, Silverio [5 ]
Tartaglione, Immacolata [5 ]
Giuditta, Marianna [3 ]
Longo, Filomena [4 ]
Origa, Raffaella [6 ]
Quarta, Antonella [7 ]
Pinto, Valeria [8 ]
Forni, Gian Luca [8 ]
机构
[1] Osped Galliera, Unita Cardiol, Genoa, Italy
[2] Osped Reg Microcitemie, ASL8, Cagliari, Italy
[3] Univ Milan, Dept Clin Sci & Commun, IRCCS Fdn Ca Granda Osped Maggiore Policlin, Milan, Italy
[4] Univ Torino, Dept Clin & Biol Sci, Turin, Italy
[5] Seconda Univ Napoli, Dipartimento Donna Bambino Chirurg Gen & Speciali, Naples, Italy
[6] Univ Cagliari, Thalassemia Unit, Dept Publ Hlth Clin & Mol Med, Cagliari, Italy
[7] Ematol Osped A Perrino, Brindisi, Italy
[8] Osped Galliera, Ematol Ctr Microcitemia & Anemie Congenite, Via Volta 6, I-16128 Genoa, Italy
关键词
Thalassemia; Heart disease; Iron overload; Serum ferritin; RANDOMIZED CONTROLLED-TRIAL; MAJOR PATIENTS; IRON OVERLOAD; MYOCARDIAL IRON; FOLLOW-UP; DEFEROXAMINE; DEFERASIROX; MANAGEMENT; COMPLICATIONS; DEFERIPRONE;
D O I
10.1007/s11739-018-1890-2
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Heart disease remains a leading cause of morbidity and mortality in transfusion-dependent thalassemia (TDT), which can be attributed to several factors but primarily develops in the setting of iron overload. This was a retrospective cohort study utilizing Webthal (R) patient data from five major centers across Italy. Patients without heart disease were followed-up for 10 years (2000-2010) and data were collected for demographics, splenectomy status, serum ferritin and hemoglobin levels, and comorbidities associated with heart disease. Among 379 patients analyzed (mean age 22.9 +/- 5.1years, 47.8% men), 44 (cumulative incidence: 11.6%) developed heart disease during the period of observation. Splenectomy (p=0.002) and serum ferritin level (p<0.001) were the only risk factors with significant association with heart disease. A serum ferritin threshold of >= 3000 ng/mL was the best predictor for the development of heart disease (86.4% sensitivity and 92.8% specificity, AUC: 0.912, 95% CI 0.852-0.971, p<0.001). On multivariate analysis, only a serum ferritin level >= 3000 ng/mL remained significantly and independently associated with increased risk of heart disease (HR: 44.85, 95% CI 18.85-106.74), with a 5- and 10-year heart disease-free survival of 58 and 39%. The association between iron overload and heart disease in patients with TDT is confirmed, yet a new serum ferritin level of 3000 ng/mL to flag increased risk is suggested.
引用
收藏
页码:365 / 370
页数:6
相关论文
共 50 条
  • [41] Reducing the iron burden and improving survival in transfusion-dependent thalassemia patients: current perspectives
    Bayanzay, Karim
    Alzoebie, Lama
    JOURNAL OF BLOOD MEDICINE, 2016, 7 : 159 - 169
  • [42] Combined chelation with high-dose deferiprone and deferoxamine to improve survival and restore cardiac function effectively in patients with transfusion-dependent thalassemia presenting severe cardiac complications
    Chuang, Tzu-Yao
    Li, Ju-Pi
    Weng, Te-Fu
    Wu, Kang-Hsi
    Chao, Yu-Hua
    ANNALS OF HEMATOLOGY, 2020, 99 (10) : 2289 - 2294
  • [43] Defining curative endpoints for transfusion-dependent β-thalassemia in the era of gene therapy and gene editing
    Corbacioglu, Selim
    Frangoul, Haydar
    Locatelli, Franco
    Hobbs, William
    Walters, Mark
    AMERICAN JOURNAL OF HEMATOLOGY, 2024, 99 (03) : 422 - 429
  • [44] A holistic approach to iron chelation therapy in transfusion-dependent thalassemia patients with serum ferritin below 500 μg/L
    Scaramellini, Natalia
    Consonni, Dario
    Cassinerio, Elena
    Arighi, Carola
    Marcon, Alessia
    Graziadei, Giovanna
    Cappellini, Maria Domenica
    Motta, Irene
    AMERICAN JOURNAL OF HEMATOLOGY, 2020, 95 (09) : E230 - E232
  • [45] Optimized serum ferritin prediction of iron overload in transfusion-dependent thalassemia: likelihood ratio and age- adjustment approach
    Kurban, Lutfi Ali
    Almarri, Bashayer Khamis
    Alshamsi, Maitha Helal
    Abdelrahman, Shahid Shehadeh
    Alwahshi, Sara Ghumail
    Alhorani, Qays
    Syed, Rizwan
    Bakoush, Omran
    ANNALS OF SAUDI MEDICINE, 2023, 43 (02) : 90 - 96
  • [46] Pulmonary dysfunction in transfusion-dependent patients with thalassemia major
    Carnelli, V
    D'Angelo, E
    Pecchiari, M
    Ligorio, M
    D'Angelo, E
    AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE, 2003, 168 (02) : 180 - 184
  • [47] Practice of iron chelation therapy for transfusion-dependent thalassemia in Southeast Asia
    Azman, Nurul Fatihah
    Abdullah, Wan-Zaidah
    Mohamad, Norsarwany
    Bahar, Rosnah
    Johan, Muhammad Farid
    Diana, R.
    Sarifah, Binti Hanafi
    Yusoff, Surini
    Nasir, Ariffin
    Othman, Azizah
    Sukeri, Surianti
    Ibrahim, Mohd Ismail
    Hussein, Adil
    Hassan, Rozita
    Yahya, Padillah
    Hassan, Rosline
    Zilfalil, Bin Alwi
    ASIAN BIOMEDICINE, 2016, 10 (06) : 537 - 547
  • [48] Leukocyte telomere length in patients with transfusion-dependent thalassemia
    Nithita Nanthatanti
    Adisak Tantiworawit
    Pokpong Piriyakhuntorn
    Thanawat Rattanathammethee
    Sasinee Hantrakool
    Chatree Chai-Adisaksopha
    Ekarat Rattarittamrong
    Lalita Norasetthada
    Wirote Tuntiwechapikul
    Kanda Fanhchaksai
    Pimlak Charoenkwan
    Sirinart Kumfu
    Nipon Chattipakorn
    BMC Medical Genomics, 13
  • [49] Efficacy and Safety of Thalidomide in Patients With Transfusion-Dependent Thalassemia
    Chandra, Jagdish
    Parakh, Nupur
    Sidharth
    Singh, Neha
    Sharma, Sunita
    Goel, Manish
    Pemde, Harish
    INDIAN PEDIATRICS, 2021, 58 (07) : 611 - 616
  • [50] Heart involvement in transfusion-dependent beta-thalassemia with conventional echocardiography
    Esfahani, Hossein
    Tanasan, Asadolah
    Rezanejad, Mina
    Torabian, Saadat
    CASPIAN JOURNAL OF INTERNAL MEDICINE, 2021, 12 (03) : 243 - 248